Durable Response to Crizotinib in a Patient with Pulmonary Adenocarcinoma Harboring MET Intron 14 Mutation: A Case Report

BACKGROUND: For patients with non-epidermal non–small-cell lung cancer (NSCLC), molecular alterations should always be investigated, especially in non-smokers, who have a very high frequency of targetable alterations (EGFR 52%; ALK 8% in particular). MET exon 14 alterations are identified in 3–4% of...

Descripción completa

Detalles Bibliográficos
Autores principales: Leyrat, Brice, Durando, Xavier, Veyssiere, Hugo, Bernadach, Maureen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8254586/
https://www.ncbi.nlm.nih.gov/pubmed/34234464
http://dx.doi.org/10.2147/OTT.S312889

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8254586/
https://www.ncbi.nlm.nih.gov/pubmed/34234464
http://dx.doi.org/10.2147/OTT.S312889

Ejemplares similares